8/16/22, 5:13 PM
`
`Bausch + Lomb Licenses New Technology with Potential to Treat Millions Affected by Ocular Redness
`
`Bausch + Lomb Licenses New
`Technology with Potential to Treat
`Millions Affected by Ocular Redness
`May Offer Faster, More Effective, Longer Lasting Relief
`
`NEWS PROVIDED BY
`Bausch + Lomb
`
`Jan 07, 2013, 07:00 ET
`
`MADISON, N.J., Jan. 7, 2013 /PRNewswire/ -- Bausch + Lomb, the global eye health company, has
`acquired an exclusive global license to a new platform technology that may lead to a faster,
`more effective and longer lasting treatment for ocular redness, a bothersome condition that
`impacts millions of people worldwide.
`
`(Logo:  http://photos.prnewswire.com/prnh/20121221/MM34011LOGO )
`
`The technology employs a different mechanism of action to relieve ocular redness than
`currently available redness relief products, using a uniquely formulated low dose of
`brimonidine. Licensed from Eye Therapies, LLC, a privately held biopharmaceutical company,
`the technology was developed in collaboration with Ora Inc., a private research organization.
`
`One of the most common ophthalmologic conditions, ocular redness, or hyperemia, can be
`triggered by contact lens wear, dry eye, ocular allergies, lifestyle and environmental factors and
`medication side effects, among other causes.
`
`https://www.prnewswire.com/news-releases/bausch--lomb-licenses-new-technology-with-potential-to-treat-millions-affected-by-ocular-redness-185856… 1/3
`
`
`
`Eye Therapies Exhibit 2124, 1 of 3
`Slayback v. Eye Therapies - IPR2022-00142
`
`

`

`8/16/22, 5:13 PM
`Bausch + Lomb Licenses New Technology with Potential to Treat Millions Affected by Ocular Redness
`"Ocular redness is associated with reduced quality of life and negative social connotations, and
`may impact compliance with certain medications," explained Dr. Cal Roberts, chief medical
`ofcer, Bausch + Lomb. "The decision to license this promising new technology underscores our
`continued commitment to delivering solutions for physicians and their patients."
`
`Currently marketed ocular redness relief therapies are often associated with problems such as
`tachyphylaxis, a decreasing response to a drug following its initial use.  This can potentially lead
`to overuse of these medications and a subsequent rebound effect, where symptoms return
`stronger upon discontinuation of a drug.
`
`In a Phase 2 study, the new technology appeared effective in reducing ocular redness based on
`both clinician assessment and patient reporting. The rebound vasoconstriction associated with
`currently available treatments was not observed in this study. Additionally, onset of action was
`shown to be rapid (within ve minutes), with a duration of effect lasting at least four hours. The
`formulation was found to be safe and well tolerated as dosed in the study, with no serious
`adverse events reported. 
`
`"The new low dose brimonidine formulation appears to provide greater microvessel
`constriction at mucosal surfaces and is thought to retain more optimal blood ow from larger
`feeder vessels," said Mark B. Abelson, M.D., CM, FRCS, FARVO, clinical professor of
`ophthalmology at Harvard Medical School and senior clinical scientist at Schepens Eye
`Research Institute. "These are promising indications that this new technology may address
`some of the issues commonly seen in current therapies."
`
`If approved, the new technology would dramatically expand Bausch + Lomb's potential to
`compete in the $350 million global ocular redness relief market, and also create opportunity to
`explore expanded ophthalmic applications.
`
`"We are proud to be working with Bausch + Lomb to develop this promising new technology,"
`said Lee Nordan, M.D., chief executive ofcer of Eye Therapies, LLC. "The company's
`commitment, expertise and resources, combined with its global reach, will help ensure that, if
`approved, this technology will reach its full potential."
`
`
`
`https://www.prnewswire.com/news-releases/bausch--lomb-licenses-new-technology-with-potential-to-treat-millions-affected-by-ocular-redness-185856… 2/3
`
`Eye Therapies Exhibit 2124, 2 of 3
`Slayback v. Eye Therapies - IPR2022-00142
`
`

`

`Bausch + Lomb Licenses New Technology with Potential to Treat Millions Affected by Ocular Redness
`
`8/16/22, 5:13 PM
`About Bausch + Lomb
`Bausch + Lomb is one of the best-known and most respected healthcare companies in the
`world. Its core businesses include contact lenses and lens care products, ophthalmic surgical
`devices and instruments, and ophthalmic pharmaceuticals. Founded in 1853, the company is
`headquartered in Rochester, N.Y., and employs roughly 11,000 people worldwide. Its products
`are available in more than 100 countries. More information is available at www.bausch.com.
`
`SOURCE Bausch + Lomb
`
`https://www.prnewswire.com/news-releases/bausch--lomb-licenses-new-technology-with-potential-to-treat-millions-affected-by-ocular-redness-185856… 3/3
`
`
`
`Eye Therapies Exhibit 2124, 3 of 3
`Slayback v. Eye Therapies - IPR2022-00142
`
`